Drug Trial Radar · NCT01396291
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)
Last checked: Nov 20, 2026Latest source record: Dec 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
561
Actual
Start
Dec 2011
Primary completion
Apr 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to evaluate the efficacy and safety of asenapine as compared to placebo in preventing the recurrence of mood episodes after stabilization of an acute/manic mixed episode in participants with Bipolar 1 Disorder. After a Screening Period, each participant will receive open-label asenapine and matching placebo for 12 to 16 weeks. Participants who meet stabilization criteria may then be randomized into one of the two study arms (asenapine or matching placebo) to receive double-blind treatment for up to an additional 26-weeks.
Conditions
- Bipolar 1 Disorder
Interventions
asenapineDrug
asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
placeboDrug
asenapine-matched placebo, sublingual tablets, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time (in days) to recurrence of any mood event during the double-blind treatment periodTime frame: From Week 12 or 16 to Week 38 or 42
Locations
80 sites in 10 countries. Site status is shown where the registry gives one.
Forest Investigative Site 3017
Anaheim, California
Forest Investigative Site 3019
Chino, California
Forest Investigative Site 3001
Escondido, California
Forest Investigative Site 3004
National City, California
Forest Investigative Site 3006
Oakland, California
Forest Investigative Site 3003
Orange, California
Forest Investigative Site 3007
Torrance, California
Forest Investigative Site 3042
Colorado Springs, Colorado
Forest Investigative Site 3012
Jacksonville, Florida
Forest Investigative Site 3040
Kissimmee, Florida
Forest Investigative Site 3031
Leesburg, Florida
Forest Investigative Site 3015
Miami, Florida
Forest Investigative Site 3010
Tampa, Florida
Forest Investigative Site 3039
Atlanta, Georgia
Forest Investigative Site 3032
Chicago, Illinois
Forest Investigative Site 3029
Schaumburg, Illinois
Forest Investigative Site 3021
Witchita, Kansas
Forest Investigative Site 3014
Gladstone, Missouri
Forest Investigative Site 3002
Albuquerque, New Mexico
Forest Investigative Site 3024
Elmsford, New York
Forest Investigative Site 3037
Avon Lake, Ohio
Forest Investigative Site 3041
Cincinnati, Ohio
Forest Investigative Site 3023
Oklahoma City, Oklahoma
Forest Investigative Site 3035
Oklahoma City, Oklahoma
Forest Investigative Site 3033
Memphis, Tennessee
Forest Investigative Site 3009
Houston, Texas
Forest Investigative Site 3020
Houston, Texas
Forest Investigative Site 3036
Irving, Texas
Forest Investigative Site 3027
Plano, Texas
Forest Investigative Site 3000
Wichita Falls, Texas
Forest Investigative Site 3102
Burgas, Bulgaria
Forest Investigative Site 3103
Varna, Bulgaria
Forest Investigative Site 3105
Pleven, Pleven, Bulgaria
Forest Investigative Site 3104
Sofia, Sofia-Grad, Bulgaria
Forest Investigative Site 3100
Sofia, Sofia-Grad, Bulgaria
Forest Investigative Site 3106
Sofia, Sofia-Grad, Bulgaria
Forest Investigative Site 3101
Varna, Varna, Bulgaria
Forest Investigative Site 3153
Zagreb, City of Zagreb, Croatia
Forest Investigative Site 3154
Zagreb, City of Zagreb, Croatia
Forest Investigative Site 3152
Zagreb, City of Zagreb, Croatia
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.